Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 8/20 | 0.69 |
| ▸ | CACNG8 | Q8WXS5 | 8/20 | 0.69 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.69 |
| ▸ | AHR | P35869 | 1/20 | 0.48 |
| ▸ | TDP2 | O95551 | 6/20 | 0.41 |
| ▸ | PTGES | O14684 | 3/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18189510 | 0.92 | GRIA1 (0.60) | GRIA1CACNG8CACNG2AHRTDP2 | |
| SCHEMBL18189528 | 0.88 | GRIA1 (0.69) | GRIA1CACNG8CACNG2AHRTDP2 | |
| SCHEMBL18189507 | 0.88 | GRIA1 (0.57) | GRIA1CACNG8CACNG2AHRTDP2 | |
| SCHEMBL18189587 | 0.85 | GRIA1 (0.54) | GRIA1CACNG8CACNG2AHRTDP2 | |
| SCHEMBL18189620 | 0.84 | GRIA1 (0.64) | GRIA1CACNG8CACNG2AHRTDP2 | |
| SCHEMBL18189558 | 0.83 | GRIA1 (0.60) | GRIA1CACNG8CACNG2TDP2 | |
| SCHEMBL18189585 | 0.82 | GRIA1 (0.62) | GRIA1CACNG8CACNG2AHRTDP2 | |
| SCHEMBL18189400 | 0.82 | GRIA1 (1.00) | GRIA1CACNG8CACNG2AHRTDP2 | |
| SCHEMBL18189568 | 0.82 | GRIA1 (0.74) | GRIA1CACNG8CACNG2AHRTDP2 | |
| SCHEMBL18189394 | 0.81 | GRIA1 (0.60) | GRIA1CACNG8CACNG2AHRTDP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107750250-B | Indolone compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-09-07 | — | — | CN | claimed |
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-31 | — | — | US | claimed |
| EP-3288935-B1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-30 | — | — | EP | claimed |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | claimed |
| EP-3288935-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | claimed |
| WO-2016176463-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | claimed |
| CN-107750250-B | Indolone compounds and their use as AMPA receptor modulators | 詹森药业有限公司 | 2021-09-07 | — | — | CN | disclosed |
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-31 | — | — | US | disclosed |
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | JANSSEN PHARMACEUTICA NV (BE) | 2020-03-31 | — | — | US | disclosed |
| EP-3288935-B1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-10-30 | — | — | EP | disclosed |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2018-05-03 | — | — | US | disclosed |
| EP-3288935-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | Janssen Pharmaceutica NV (BE) | 2018-03-07 | — | — | EP | disclosed |
| WO-2016176463-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10604484-B2 | Indolone compounds and their use as AMPA receptor modulators | GRIN3A, GRIN1, GRIN2B | GRIA1 23/4885CACNG8 317/4885CACNG2 370/4885 |
| US-20180118683-A1 | INDOLONE COMPOUNDS AND THEIR USE AS AMPA RECEPTOR MODULATORS | GRIN3A, GRIN1, GRIN2B | GRIA1 23/4885CACNG8 317/4885CACNG2 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.